Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine Priming and Maintenance in AML
NCT06180863Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Nov 2023
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Yale University. Planned start Nov 2023; status: withdrawn.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06180863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180863.